T3D-959 Phase 2 Results to Be Presented at AAIC on Reducing Alzheimer's Amyloid Plaque

New cognition/function and extensive plasma biomarker results of T3D-959 treatment from the Phase 2 PIONEER trial, in a modified intent-to treat population of mild to moderate Alzheimer's patients will be presented at the upcoming Alzheimer's Association International Conference (AAIC) in Philadelphia, PA from July 28 to August 1.

T3D-959 is a novel, orally delivered, once-a-day, small molecule drug candidate, designed to activate two nuclear receptors regulating brain glucose energy and lipid metabolism to improve brain health and function.

T3D Therapeutics, Inc., a clinical stage drug development company engaged in the development of a new orally administered treatment for Alzheimer's disease (AD), announced that CEO, John Didsbury, will be presenting new Phase 2 results in a modified intent-to-treat population of mild to moderate Alzheimer's patients at AAIC. The poster presentation will take place on Sunday, July 28th in Philadelphia, PA.

Presentation Details:
Title: Phase 2 PIONEER Trial of Oral T3D-959 for the Treatment of Patients Diagnosed with Mild-to-Moderate Alzheimer's Disease: New Results in a Modified Intent-to-Treat Population
Session: Developing Topics: Drug Development
Poster Number: Sunday-798
Abstract Number: 95625
Date/Time: July 28, 2024, 8:00am-4:15pm (ET)
Location: Pennsylvania Convention Center, Exhibit Hall (Hall BC)

John Didsbury stated, "AD is a disease that encompasses a plethora of neurodegenerative 'triggers' including beta amyloid plaques, tau neurofibrillary bundles, oxidative stress, neuroinflammation and neurotransmitter deficits. Altered glucose and lipid brain metabolism is at its core. Improving brain metabolism can impact these neurodegenerative triggers, including reducing amyloid plaque burden. Current AD drug development is highly focused on plaque reduction, but recently-marketed therapies are not ideal in terms of safety and delivery. The novel mechanism of action, oral once-a-day administration, and safety profile of T3D-959 offers the potential to address the deficiencies of anti-plaque antibodies."

About T3D-959: T3D-959, a small molecule, delivered orally once daily, is a brain-penetrating PPAR delta/gamma dual nuclear receptor agonist designed to improve both glucose and lipid metabolism dysfunctions present in AD and other neurodegenerative disorders.

About the Study: The Phase 2 PIONEER study (Prospective therapy to Inhibit and Overcome Alzheimer's Disease Neurodegeneration via Brain EnErgetics and Metabolism Restoration) was a double-blind, placebo-controlled, parallel-group Phase 2 safety and efficacy study that enrolled 250 adults with mild-to-moderate Alzheimer's disease (MMSE 14-26). PIONEER was designed to assess the safety, tolerability, and effectiveness of T3D-959 in the treatment of Alzheimer's disease. T3D-959 was administered orally once daily over a 24-week dosing period. Subjects received one of three different doses of T3D-959 (15mg, 30mg, or 45mg) or a placebo.

PIONEER is supported by the National Institute on Aging, part of the National Institutes of Health, under award number R01AG061122 and by the Alzheimer's Association's Part the Cloud Gates Partnership Grant Program.

About T3D Therapeutics, Inc.: T3D Therapeutics, Inc. is a privately held, Research Triangle Park, NC-based company. The Company has an exclusive license to T3D-959, its lead product candidate, and a platform of structurally related molecules. T3D Therapeutics' mission is to develop and commercialize T3D-959 for the treatment of Alzheimer's disease.